|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy显示文摘Hepatitis due to hepatitis B virus(HBV) reactivation can be severe and potentially fatal, but is preventable. HBV reactivation is most commonly reported in patients receiving cancer chemotherapy, especially rituximabcontaining therapy for hematological malignancies and those receiving stem cell transplantation. All patients with hematological malignancies receiving anticancer therapy should be screened for active or resolved HBV infection by blood tests for hepatitis B surface antigen(HBs Ag) and antibody to hepatitis B core antigen(antiHBc). Patients found to be positive for HBs Ag should be given prophylactic antiviral therapy to prevent HBV reactivation. For patients with resolved HBV infection, no standard strategy has yet been established to prevent HBV reactivation. There are usually two options. One is pre-emptive therapy guided by serial HBV DNA monitoring, whereby antiviral therapy is given as soon as HBV DNA becomes detectable. However, there is little evidence regarding the optimal interval and period of monitoring. An alternative approach is prophylactic antiviral therapy, especially for patients receiving highrisk therapy such as rituximab, newer generation of anti-CD20 monoclonal antibody, obinutuzumab or hematopoietic stem cell transplantation. This strategy may effectively prevent HBV reactivation and avoid the inconvenience of repeated HBV DNA monitoring. Entecavir or tenofovir are preferred over lamivudine as prophylactic therapy. Although there is no well-defined guideline on the optimal duration of prophylactic therapy, there is growing evidence to recommend continuing prophylactic antiviral therapy for at least 12 mo after cessation of chemotherapy, and even longer for those who receive rituximab or who had high serum HBV DNA levels before the start of immunosuppressive therapy. Many novel agents have recently become available for the treatment of hematological malignancies, and these agents may be associated with HBV reactivation. Although there is currently limited evidence to guide the optimal preventive measures, we recommend antiviral prophylaxis in HBs Ag-positive patients receiving novel treatments, especially the Bruton tyrosine kinase inhibitors and the phosphatidylinositol 3-kinase inhibitors, which are B-cell receptor signaling modulators and reduce proliferation of malignant B-cells. Further studies are needed to clarify the risk of HBV reactivation with these agents and the best prophylactic strategy in the era of targeted therapy for hematological malignancies. | Man Fai Law Rita Ho Carmen KM Cheung Lydia HP Tam Karen Ma Kent CY So Bonaventure Ip Jacqueline So Jennifer Lai Joyce Ng Tommy HC Tam | 2016 | World Journal of Gastroenterology2016，22，28： | 10 |
| 2 | Association of plasminogen activators and matrix metalloproteinase-9 proteolytic cascade with blood-CNS barrier damage of angiostrongyliasis显示文摘 | Chen KM Liu JY Lai SC | 2006 | Int J Exp Pathol2006，87，2： | 1 |
| 3 | Association of plasminogen activators and matrix metalloproteinase-9 proteolytic cascade with blood-CNS barrier damage of angiostrongyliasis显示文摘 | Chen KM Liu JY Lai SC | 2006 | Int J Exp Pathol2006，87，2： | 1 |
| 4 | Lansoprazole for the prevention of recurrences of ulcer complications from long term low dose aspirin use显示文摘 | Lai KC Lam SK Chu KM | 2002 | N Engl J Med2002，346，26： | 1 |
| 5 | A New PWM Con-troller with One-cycle Response显示文摘 | SMITH KM LAI Z R SMEDLEY KM | 1999 | IEEE Transaction On Power Electronics1999，14，1： | 1 |
| 6 | Synergistic interaction between Astragali Radix and Rehmanniae Radix in a Chinese herbal for- nmla to promote diabetic wound healing显示文摘 | Lau KM Lai KK Liu CL | 2012 | J Ethnopharmacol2012，141，1： | 1 |
| 7 | Efficacy of albendazole GM6001co therapy against Angiostrongylus cantonensis induced meningitisin BALB/c mice显示文摘 | Lai SC Jiang ST Chen KM | 2005 | Acta Trop2005，93，3： | 1 |
| 8 | Managing anterior capsule contraction by mechanical widening with vitrector-cut capsulotomy显示文摘 | Yeh PC Goins KM Lai WW | 2002 | J Cataract Refract Surg2002，28，2： | 1 |
| 9 | Mycophenolate mofetil in lupus glomerulonephritis 显示文摘 | Lai KM | 2002 | Am J Kindney Dis2002，40，： | 1 |
| 10 | Comparative efficacies of al bendazole and the Chinese herbal medicine long dan xie gan tan,used alone or in combination,in the treatment of experimental eosin ophilic meningitis induced by Angiostrongylus cantonensis显示文摘 | Lai SC Chen KM Chang YH | 2008 | AnnTrop Med Parasitol2008，102，2： | 1 |
| 11 | Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy 显示文摘 | Lai KM Gonzalez M Poueymirou WT | 2004 | Mol Cell Biol2004，24，21： | 1 |
| 12 | Lansoprazole for the prevention of recurrences of ulcer complications from long term low-dose aspirin use显示文摘 | Lai KC Lam SK Chu KM | 2002 | N Engl J Med2002，346，26： | 1 |
| 13 | Alterations of high-energy phosphate, serum energy substrate and their metabolites after partial hepatectomy in rats 显示文摘 | Lai HS Chen WJ Chen KM | 1991 | J Formos Med Assoc1991，90，7： | 1 |
| 14 | Differential effects of transforming growth factor-beta on the synthesis of connective tissue growth factor and vascular endothelial growth factor by peritoneal mesothelial cell显示文摘 | SZETOCC LAI KB CHOW KM | 2005 | Nephron Exp Nephrol2005，99，4： | 1 |
| 15 | Retrievable inferior vena eava filters:initial clinieal results显示文摘 | Rosenthal D Wellons ED Lai KM | 2006 | Ann Vasc Surg2006，20，1： | 1 |
| 16 | The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis 显示文摘 | Saucier C Khoury H Lai KM | 2004 | Proc Natl Acad Sci USA2004，101，8： | 1 |
| 17 | The Shc adaptorproteiu is critical for VEGF induction by Met/HGF and ErbB2 re- ceptors and for early onset of tumor angiogenesis 显示文摘 | Saucier C Khoury I~ Lai KM | 2004 | Proc Natl Acad Sci USA2004，101，8： | 1 |
| 18 | Retrievable inferior vena cava fihers : initial clinical results 显示文摘 | Rosenthal D Wellons ED Lai KM | 2006 | Ann Vasc Surg2006，20，1： | 1 |
| 19 | Exogenous expression of human apoA-I enhances cardiac differentiation of pluripotent stem cells显示文摘 | Ng KM Lee YK Lai WH | | 0，，05： | 1 |
| 20 | Retrievable inferior vena cava filters:initial clinical results显示文摘 | Rosenthal D Wellons ED Lai KM | | 0，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员